Annovis Bio, Inc. (ANVS)

18.80 +0.33 (+1.79%) At close: 04:00PM EDT

Annovis Bio, Inc.

1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
United States
610 727 3913
https://www.annovisbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Maria L. Maccecchini Ph.D.	Founder, CEO, Pres & Exec. Director	791.6k	N/A	1951
Mr. Henry Hagopian III, M.B.A.	Chief Financial Officer	N/A	N/A	1968
Dr. Cheng Fang Ph.D.	Sr. VP of R&D	N/A	N/A	N/A
Ms. Eve M. Damiano M.S., RAC	Sr. VP of Regulatory Operations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Corporate Governance

Annovis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.